FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2950093013> ?p ?o ?g. }

• W2950093013 endingPage "842" @default.
• W2950093013 startingPage "833" @default.
• W2950093013 abstract "Background Antibiotic-resistant gonorrhoea represents a global public health threat, and new therapies are needed. We aimed to compare the efficacy and safety of solithromycin, a fourth generation macrolide, with ceftriaxone plus azithromycin for the treatment of gonorrhoea. Methods We did an open-label, multicentre, non-inferiority trial of patients aged 15 years or older with uncomplicated untreated genital gonorrhoea at two sites in Australia and one site in the USA. Patients were randomly assigned (1:1) to receive single dose oral solithromycin 1000 mg or intramuscular ceftriaxone 500 mg plus oral azithromycin 1000 mg. Neisseria gonorrhoeae cultures were obtained at baseline and test of cure (day 7 ± 2). The primary outcome was the proportion of patients with eradication of genital N gonorrhoeae based on culture at test of cure, assessed in the microbiological intention-to-treat (mITT) population, which included all randomly assigned patients who received any dose of study drug and had a positive genital culture for N gonorrhoeae at baseline. Non-inferiority of solithromycin was to be concluded if the lower limit of the 95% CI for the between-group differences was greater than −10%. Safety was analysed in all patients who received any dose of study drug. This trial is registered with ClinicalTrials.gov, number NCT02210325. Findings Between Sept 3, 2014, and Aug 27, 2015, 262 patients were randomly assigned and 261 received treatment (130 in the solithromycin group and 131 in the ceftriaxone plus azithromycin group). In the mITT population, 99 (80%) of 123 patients in the solithromycin group and 109 (84%) of 129 patients in the ceftriaxone plus azithromycin group had N gonorrhoeae eradication at test of cure (difference −4·0%, 95% CI −13·6 to 5·5), thus solithromycin did not meet the criterion for non-inferiority at the prespecified −10% margin. The frequency of adverse events was higher in the solithromycin group than the ceftriaxone plus azithromycin group (69 [53%] of 130 patients vs 45 [34%] of 131 patients), the most common of which were diarrhoea (31 [24%] of 130 patients vs 20 [15%] of 131 patients), and nausea (27 [21%] of 130 patients vs 15 [11%] of 131 patients). Interpretation Solithromycin as a single 1000 mg dose is not a suitable alternative to ceftriaxone plus azithromycin as first-line treatment for gonorrhoea. If insufficient duration of solithromycin exposure at the infection site in a subset of individuals was the reason for treatment failures, this might be adequately addressed with dose adjustment. However, any further trials with longer dosing need to consider the potential risk of gastrointestinal effects and liver enzyme elevations. Funding Cempra Pharmaceuticals." @default.
• W2950093013 created "2019-06-27" @default.
• W2950093013 creator A5002105758 @default.
• W2950093013 creator A5003244996 @default.
• W2950093013 creator A5012937961 @default.
• W2950093013 creator A5032600080 @default.
• W2950093013 creator A5035436227 @default.
• W2950093013 creator A5045084750 @default.
• W2950093013 creator A5056904986 @default.
• W2950093013 creator A5062218086 @default.
• W2950093013 creator A5065984680 @default.
• W2950093013 creator A5067622825 @default.
• W2950093013 creator A5072667689 @default.
• W2950093013 creator A5083362446 @default.
• W2950093013 creator A5086010156 @default.
• W2950093013 creator A5089036530 @default.
• W2950093013 date "2019-08-01" @default.
• W2950093013 modified "2023-10-18" @default.
• W2950093013 title "Solithromycin versus ceftriaxone plus azithromycin for the treatment of uncomplicated genital gonorrhoea (SOLITAIRE-U): a randomised phase 3 non-inferiority trial" @default.
• W2950093013 cites W1994449629 @default.
• W2950093013 cites W1996792558 @default.
• W2950093013 cites W2031703906 @default.
• W2950093013 cites W2035615368 @default.
• W2950093013 cites W2085221214 @default.
• W2950093013 cites W2095304415 @default.
• W2950093013 cites W2097274712 @default.
• W2950093013 cites W2099207046 @default.
• W2950093013 cites W2113427258 @default.
• W2950093013 cites W2121417259 @default.
• W2950093013 cites W2122114488 @default.
• W2950093013 cites W2122633654 @default.
• W2950093013 cites W2123386797 @default.
• W2950093013 cites W2127995782 @default.
• W2950093013 cites W2147292570 @default.
• W2950093013 cites W2151098242 @default.
• W2950093013 cites W2171453996 @default.
• W2950093013 cites W2192116738 @default.
• W2950093013 cites W2231652168 @default.
• W2950093013 cites W2268368058 @default.
• W2950093013 cites W2464932009 @default.
• W2950093013 cites W2484777715 @default.
• W2950093013 cites W2525535909 @default.
• W2950093013 cites W2558322962 @default.
• W2950093013 cites W2607267328 @default.
• W2950093013 doi "https://doi.org/10.1016/s1473-3099(19)30116-1" @default.
• W2950093013 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31196813" @default.
• W2950093013 hasPublicationYear "2019" @default.
• W2950093013 type Work @default.
• W2950093013 sameAs 2950093013 @default.
• W2950093013 citedByCount "37" @default.
• W2950093013 countsByYear W29500930132019 @default.
• W2950093013 countsByYear W29500930132020 @default.
• W2950093013 countsByYear W29500930132021 @default.
• W2950093013 countsByYear W29500930132022 @default.
• W2950093013 countsByYear W29500930132023 @default.
• W2950093013 crossrefType "journal-article" @default.
• W2950093013 hasAuthorship W2950093013A5002105758 @default.
• W2950093013 hasAuthorship W2950093013A5003244996 @default.
• W2950093013 hasAuthorship W2950093013A5012937961 @default.
• W2950093013 hasAuthorship W2950093013A5032600080 @default.
• W2950093013 hasAuthorship W2950093013A5035436227 @default.
• W2950093013 hasAuthorship W2950093013A5045084750 @default.
• W2950093013 hasAuthorship W2950093013A5056904986 @default.
• W2950093013 hasAuthorship W2950093013A5062218086 @default.
• W2950093013 hasAuthorship W2950093013A5065984680 @default.
• W2950093013 hasAuthorship W2950093013A5067622825 @default.
• W2950093013 hasAuthorship W2950093013A5072667689 @default.
• W2950093013 hasAuthorship W2950093013A5083362446 @default.
• W2950093013 hasAuthorship W2950093013A5086010156 @default.
• W2950093013 hasAuthorship W2950093013A5089036530 @default.
• W2950093013 hasConcept C126322002 @default.
• W2950093013 hasConcept C168563851 @default.
• W2950093013 hasConcept C197934379 @default.
• W2950093013 hasConcept C203014093 @default.
• W2950093013 hasConcept C2776520383 @default.
• W2950093013 hasConcept C2778082588 @default.
• W2950093013 hasConcept C2778907293 @default.
• W2950093013 hasConcept C2779166590 @default.
• W2950093013 hasConcept C2908647359 @default.
• W2950093013 hasConcept C3013748606 @default.
• W2950093013 hasConcept C501593827 @default.
• W2950093013 hasConcept C71924100 @default.
• W2950093013 hasConcept C86803240 @default.
• W2950093013 hasConcept C89423630 @default.
• W2950093013 hasConcept C99454951 @default.
• W2950093013 hasConceptScore W2950093013C126322002 @default.
• W2950093013 hasConceptScore W2950093013C168563851 @default.
• W2950093013 hasConceptScore W2950093013C197934379 @default.
• W2950093013 hasConceptScore W2950093013C203014093 @default.
• W2950093013 hasConceptScore W2950093013C2776520383 @default.
• W2950093013 hasConceptScore W2950093013C2778082588 @default.
• W2950093013 hasConceptScore W2950093013C2778907293 @default.
• W2950093013 hasConceptScore W2950093013C2779166590 @default.
• W2950093013 hasConceptScore W2950093013C2908647359 @default.
• W2950093013 hasConceptScore W2950093013C3013748606 @default.
• W2950093013 hasConceptScore W2950093013C501593827 @default.
• W2950093013 hasConceptScore W2950093013C71924100 @default.
• W2950093013 hasConceptScore W2950093013C86803240 @default.

• next